UGT1A1 Genotype-guided Phase I Study of Irinotecan, Oxaliplatin, and Capecitabine

PURPOSE: We performed a UGT1A1 genotype-guided study to determine the maximum tolerated dose (MTD) and evaluate the toxicities and pharmacokinetics of the combination of capecitabine (CAP), oxaliplatin (OX), and irinotecan (IRIN). EXPERIMENTAL DESIGN: Patients were screened for UGT1A1 *28 genotype p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Goetz, Matthew P., McKean, Heidi A., Reid, Joel M, Mandrekar, Sumithra J., Tan, Angelina D., Kuffel, Mary A., Safgren, Stephanie L., McGovern, Renee M., Goldberg, Richard M., Grothey, Axel A., McWilliams, Robert, Erlichman, Charles, Ames, Matthew M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3880122/
https://ncbi.nlm.nih.gov/pubmed/24114122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0034-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky